Urinary tract infection

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat

Retrieved on: 
Friday, March 15, 2024
Woman, ITRM, Infection, Therapy, Urinary tract infection, Event

DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, announced today that the company will participate in a virtual H.C. Wainwright @Home Fireside Chat on March 21, 2024.

Key Points: 
  • DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, announced today that the company will participate in a virtual H.C. Wainwright @Home Fireside Chat on March 21, 2024.
  • Corey Fishman, Iterum’s Chief Executive Officer, Sailaja Puttagunta, M.D., Iterum’s Chief Medical Officer, and Judy Matthews, Iterum’s Chief Financial Officer, will discuss Iterum’s lead program, oral sulopenem, for the treatment of adult women with uncomplicated urinary tract infections (uUTI).
  • The webcast presentation replay will be available for viewing on the Events & Presentations section of Iterum’s website following the presentation.

Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Retrieved on: 
Thursday, March 14, 2024
Phase, Urinary tract infection, Patient, Pyelonephritis, ASX, RCE, Recce, Pharmaceutical industry

The next cohort of healthy subjects dosed at 3,000mg over 20 minutes, with the remaining subjects to be dosed over the coming days

Key Points: 
  • The next cohort of healthy subjects dosed at 3,000mg over 20 minutes, with the remaining subjects to be dosed over the coming days
    RECCE® 327 now tested at four infusion times, achieving these timestamps in line with intended future regulatory submissions
    SYDNEY, Australia, March 14, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it dosed the next cohort of healthy subjects at 3,000mg within a fast infusion rate of 20-minutes in a Phase I/II trial evaluating its lead candidate, RECCE® 327 (R327).
  • “We're pleased to continue advancing the clinical profile of R327, which has demonstrated safe and efficacious potential against a broad range of antibiotic-resistant pathogens across multiple studies,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • The Company has established that the dose of 3,000mg, administered at varying infusion times between 15 and 60 minutes, has been proven safe in participants.
  • The efficacy of R327 via intravenous administration will be made available at the completion of the Phase I/II trial in line with the study protocol.

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Retrieved on: 
Wednesday, March 13, 2024
Gram-negative bacteria, Department of Defence, Urinary tract infection, GSK, Patient, Human services, Quality of life, IND, Tebipenem, Clinical trial, Therapy, Infection, Research, Policy, Treasurer, Carbapenem-resistant enterobacteriaceae, Safety, Pharmacokinetics, Federal, Food, AP, Drug discovery, Disease, Kidney, SPA, Acinetobacter baumannii, MDR, Pyelonephritis, Annual report, FDA, Army, HBR, Government, Unitary state, NTM, Assistant, Fungal infection, Pseudomonas aeruginosa, Hope, National Institutes of Health, ID, Mycobacterium avium complex, Bangladesh Technical Education Board, Administration, Pharmaceutical industry

“2023 was a productive year for Spero and we have been focused on execution across our programs,” said Sath Shukla, President, and Chief Executive Officer of Spero.

Key Points: 
  • “2023 was a productive year for Spero and we have been focused on execution across our programs,” said Sath Shukla, President, and Chief Executive Officer of Spero.
  • Top-line data from the Phase 2a proof-of-concept clinical trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients is expected in 2H 2024.
  • Spero commenced enrollment in PIVOT-PO, a global, randomized, double-blind, Phase 3 clinical trial of tebipenem HBr in patients with cUTI, including AP in December 2023.
  • Total revenue for the fourth quarter of 2023 was $73.5 million, compared with total revenue of $47.4 million for the fourth quarter of 2022.

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

Retrieved on: 
Saturday, April 6, 2024
Research, Women, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, Oncology, Orbis, Urinary tract infection, Cardiac arrest, Stomatitis, Patient, Stroke, Lung cancer, University, Acute kidney injury, Neoplasm, Therapy, Anemia, Vomiting, Pleural effusion, Cellulitis, Shock (mechanics), Periodic breathing, Colorectal cancer, Abdominal pain, Safety, Immunohistochemistry, Fatigue, ADC, Daiichi Sankyo, Food, IHC, Sepsis, NSCLC, Appetite, Biliary tract, Constipation, NCCN, MD, Priority review, Fatality, Pneumonitis, HER2, ILD, Medication, Pneumonia, AstraZeneca, COVID-19, Biomarker, Diarrhea, Bleeding, MD Anderson Cancer Center, Nausea, Upper respiratory tract infection, Pharmaceutical industry

The first tumor agnostic approval of a HER2 directed therapy and ADC was based on efficacy data in 192 adult patients with previously treated unresectable or metastatic HER2 positive (IHC 3+) solid tumors who were enrolled in one of three multicenter phase 2 trials from the DESTINY clinical development program, including DESTINY-PanTumor02 , DESTINY-Lung01 or DESTINY-CRC02 .

Key Points: 
  • The first tumor agnostic approval of a HER2 directed therapy and ADC was based on efficacy data in 192 adult patients with previously treated unresectable or metastatic HER2 positive (IHC 3+) solid tumors who were enrolled in one of three multicenter phase 2 trials from the DESTINY clinical development program, including DESTINY-PanTumor02 , DESTINY-Lung01 or DESTINY-CRC02 .
  • In DESTINY-PanTumor02, efficacy was assessed in a subgroup of previously treated patients (n=111) with centrally or locally assessed HER2 positive (IHC 3+) solid tumors including either biliary tract, bladder, cervical, endometrial, ovarian, pancreatic or other tumors.
  • In DESTINY-Lung01, efficacy was assessed in a subgroup of patients (n=17) with centrally confirmed HER2 positive (IHC 3+) non-small cell lung cancer (NSCLC).
  • In DESTINY-CRC02, efficacy was assessed in the subgroup of patients (n=64) with centrally confirmed HER2 positive (IHC 3+) colorectal cancer.

Ketolides Market Expects Robust Growth With Rising Infectious Disease Prevalence - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Infectious Diseases, Pharmaceutical, Health, Ketolide, Sinusitis, Pharmacy, Infection, Urinary tract infection, Hospital, Prevalence, Antimicrobial stewardship, Tuberculosis, Pharmaceutical industry

The global ketolides market is poised for steady expansion, driven by the growing need for effective treatments for infectious diseases and an upsurge in healthcare investments.

Key Points: 
  • The global ketolides market is poised for steady expansion, driven by the growing need for effective treatments for infectious diseases and an upsurge in healthcare investments.
  • According to the latest market research report, the ketolides market showcases a promising compound annual growth rate (CAGR), signaling a positive trajectory from $3.07 billion in 2023 to a projected value of $3.82 billion by 2028.
  • It also identifies emerging trends in targeted therapies and advancements in diagnostic procedures that are augmenting the ketolides market landscape.
  • The report underscores North America's dominance in the ketolides arena, attributable to robust healthcare infrastructure, comprehensive screening programs, and a heightened focus on infectious disease control.

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Retrieved on: 
Friday, March 22, 2024
FDA, Health, Other Health, Pharmaceutical, Cardiology, Biotechnology, Photograph, Glucose, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, European Medicines Agency, Ezetimibe, Therapy, Anemia, Pain, Sinusitis, Esperion Therapeutics, Bempedoic acid, Abdominal pain, Risk, Gout, Webcast, Committee, Spasm, Splenic infarction, ESPR, Back pain, ATP, Safety, Membrane protein, Fatigue, CHMP, Arthralgia, Angioedema, U.S. FDA, Cardiovascular disease, Kidney, Constipation, Death, Adverse event, Pregnancy, CLEAR, Rash, Rupture, Molina Healthcare, Hypersensitivity, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Multimedia, Uric acid, Dietary supplement

In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.

Key Points: 
  • In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.
  • They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
  • View the full release here: https://www.businesswire.com/news/home/20240322544788/en/
    U.S. FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

MedStar Health and DispatchHealth Launch Exclusive Partnership to Provide Acute Care at Home in Washington, D.C.

Retrieved on: 
Thursday, April 4, 2024
EDS, Innovation, Pneumonia, Practitioner, Caregiver, Partnership, MedStar Health, MedSTAR, Risk, COVID-19, Health, Patient, Education, MedStar Georgetown University Hospital, MD, Dehydration, Urinary tract infection, Emergency medicine, COPD, MedStar Washington Hospital Center, Multimedia

"MedStar Health is committed to expanding the continuity of the safest and highest quality care through a unique new partnership in Washington, D.C.," says Ethan Booker, MD , chief medical officer for telehealth at MedStar Health and a leader of MedStar Institute for Innovation.

Key Points: 
  • "MedStar Health is committed to expanding the continuity of the safest and highest quality care through a unique new partnership in Washington, D.C.," says Ethan Booker, MD , chief medical officer for telehealth at MedStar Health and a leader of MedStar Institute for Innovation.
  • This at-home acute care service is preventing hospital returns by providing care that can be managed in a patient's own home, such as medication management.
  • DispatchHealth securely sends information and follow-up requests from visits with the patients' care teams at MedStar Health.
  • "It's a privilege to collaborate with MedStar Health and its high-quality care teams through this partnership."

Samaritan Health Services Partners with KeyCare to Offer 24x7 Virtual Care via Epic-based Platform

Retrieved on: 
Tuesday, March 26, 2024
Headache, Sting, Biting, Partnership, Toothache, Patient, Hospital, Constipation, Samaritan Health Services, Common, Nausea, Ground substance, Back pain, Urinary tract infection, Sprain, Fever, Allergy, Vomiting, Health

CHICAGO, March 26, 2024 /PRNewswire/ -- KeyCare, the nation's first Epic-based virtual care company, announced today that it has partnered with Samaritan Health Services to provide 24x7, national virtual urgent care services to their patients. 

Key Points: 
  • Oregon-based health system serving rural patients to offer convenient access to 24/7, on-demand virtual urgent care through MyChart
    CHICAGO, March 26, 2024 /PRNewswire/ -- KeyCare , the nation's first Epic-based virtual care company, announced today that it has partnered with Samaritan Health Services to provide 24x7, national virtual urgent care services to their patients.
  • Samaritan patients can now obtain virtual urgent care wherever and whenever needed by conducting a virtual visit through the MyChart patient portal.
  • "Our partnership with KeyCare ensures that we can immediately expand access for virtual urgent care to meet our patient demand, while allowing us to add other virtual services offerings over time."
  • "We are thrilled to be able to help Samaritan Health Services expand access to care for its patient population, and especially fortunate to have Samaritan as our first health system partner in Oregon.

Wyeth launches China's first infant formula with two types of HMOs, leading the way in HMO innovation

Retrieved on: 
Monday, March 25, 2024
Trial of the century, Urinary tract infection, Health maintenance organization, Hospital, Research, HMO, Bronchitis, Xinhua Hospital, Infant

It diminishes lower respiratory tract infections by 55%, bronchitis by 70%, and the likelihood of using antibiotics by 53%.

Key Points: 
  • It diminishes lower respiratory tract infections by 55%, bronchitis by 70%, and the likelihood of using antibiotics by 53%.
  • Meanwhile, based on this ground-breaking innovation, the domestic HMO clinical study project for Chinese infants has officially started.
  • Ms. Shiela Qiu, Regional Business Head, Wyeth Nutrition Greater China Region, stated, "We are thrilled to achieve another milestone in the Chinese infant nutrition market.
  • Wyeth Nutrition is dedicated to fostering the superior growth of the Chinese infant nutrition market, bringing together worldwide research resources and quickening local innovation, and offering Chinese newborns more complete early-life nutrition options."

Wyeth launches China's first infant formula with two types of HMOs, leading the way in HMO innovation

Retrieved on: 
Monday, March 25, 2024
HMO, Xinhua Hospital, Bronchitis, Health maintenance organization, Hospital, Research, Infant, Trial of the century, Urinary tract infection, Multimedia

This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months.

Key Points: 
  • This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months.
  • It diminishes lower respiratory tract infections by 55%, bronchitis by 70%, and the likelihood of using antibiotics by 53%.
  • Meanwhile, based on this ground-breaking innovation, the domestic HMO clinical study project for Chinese infants has officially started.
  • Ms. Shiela Qiu, Regional Business Head, Wyeth Nutrition Greater China Region, stated, "We are thrilled to achieve another milestone in the Chinese infant nutrition market.